Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preventive Effectiveness of Primary Care Physician-led CGM-supported Comprehensive Intervention on Cardio-metabolic-immune Diseases in Community Patients With Type 2 Diabetes (Community Diabetes Control Project) -A Cluster Randomized, Open-label, Controlled Trial

NCT07885904 is registered in ClinicalTrials.gov with Xiangya Hospital of Central South University as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07885904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Preventive Effectiveness of Primary Care Physician-led CGM-supported Comprehensive Intervention on Cardio-metabolic-immune Diseases in Community Patients With Type 2 Diabetes (Community Diabetes Control Project) -A Cluster Randomized, Open-label, Controlled Trial
Lead sponsor
Xiangya Hospital of Central South University
Phase
Not applicable
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
December 30, 2030
Enrollment
15,400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus

Arms

As registered; 2 arms.

  • intervention group Experimentalcomprehensive intervention

    Medication, diet and exercise intervention

  • no intervention No intervention

Primary endpoints

Registered primary outcome measures; 2 primary.

  • Percentage of Participants Achieving Glycated Hemoglobin (HbA1c) <7.0% 6 months after randomization

    The percentage of participants with glycated hemoglobin (HbA1c) below 7.0% at 6 months after randomization. HbA1c will be measured using high-performance liquid chromatography in a laboratory certified under a national HbA1c standardization program and reported as a percentage (%).

  • Time to First Composite Cardio-Metabolic-Immune Clinical Outcome From randomization through 36 months

    Time in days from randomization to the first independently adjudicated event: cardiovascular death; nonfatal myocardial infarction; nonfatal ischemic or hemorrhagic stroke; heart failure hospitalization; end-stage kidney disease (long-term dialysis, kidney transplantation, or sustained eGFR \<15 mL/min/1.73 m2); hospitalization for diabetic foot ulcer/infection/gangrene or diabetes-related lower-limb amputation; sight-threatening diabetic retinopathy requiring retinal laser, intravitreal therapy, or surgery or new diabetes-related blindness; hospitalization for diabetic ketoacidosis or hyperosmolar hyperglycemic state; or new moderate-to-severe immune-mediated inflammatory disease (rheumatoid arthritis; psoriasis/psoriatic arthritis; Crohn disease/ulcerative colitis; systemic lupus erythematosus; or another disease prespecified in the endpoint charter). An independent blinded endpoint committee will adjudicate events from clinical records.

Lead sponsor's other trials

Xiangya Hospital of Central South University, most recent start first.

Similar trials

Same condition (Diabetes Mellitus, Type 2) and phase, most recent start first.